Takeda in talks to buy rival Nycomed
Japan's largest drug maker Takeda Pharmaceutical is in talks to buy its privately held Swiss rival Nycomed for more than $12bn (£7bn) in an attempt to extend its global reach into Europe and emerging markets.
The purchase would offer the mainly Asia and US-focused maker of drugs for diabetes and heart disease access to a lung disease drug, Daxas, just approved in the United States, and a portfolio of over-the-counter consumer products.
A Nycomed deal would be Japan's second-biggest overseas takeover according to Thomson Reuters data – after Japan Tobacco's $19bn buy of Britain's Gallagher – and would be a second major deal for Takeda after it bought the US cancer drug specialist Millennium Pharmaceuticals in 2008 for about $9bn.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies